The present disclosure relates to the use of anti-platelet agents for the treatment of thrombosis and related conditions in a subject. The anti-platelet agent, preferably a phosphoinositide 3-kinase beta (PI3Kβ) inhibitor such as TGX221 or AZD6482, may be administered alone or in combination with a thrombolytic agent, preferably recombinant tissue plasminogen activator (rtPA), and/or an anticoagulant agent, preferably argatroban.

The present disclosure relates to the use of anti-platelet agents for the treatment of thrombosis and related conditions in a subject. The anti-platelet agent, preferably a phosphoinositide 3-kinase beta (PI3Kβ) inhibitor such as TGX221 or AZD6482, may be administered alone or in combination with a thrombolytic agent, preferably recombinant tissue plasminogen activator (rtPA), and/or an anticoagulant agent, preferably argatroban.

Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.

Devices, methods and systems are provided for isolating extracellular matrix bodies. More particularly, this invention discloses devices, methods and systems for isolating extracellular matrix bodies from a biological sample for use in diagnosis and prognosis of a subject. A device may have restriction channels for isolating extracellular matrix bodies and uniform flow channels for precise pressure measurements.

The present invention provides compositions comprising one or more active pharmaceutical ingredients, wherein the compositions are in the form of high solids concentration pastes capable of being injected in relatively low volumes into an animal using standard commercially available syringes. The invention also provides methods of making such compositions, particularly those compositions comprising high molecular weight active ingredients (e.g., antibodies, enzymes and other proteins and peptides) at relatively high therapeutic concentrations in the high solids concentration pastes. The invention further provides methods of using such formulations in treating, preventing and/or ameliorating certain diseases and physical disorders in animals, including humans, in need thereof. The invention also provides kits comprising the formulations of the invention and a suitable syringe, which in some aspects may be pre-loaded or pre-filled with a composition of the invention.

The present invention provides compositions comprising one or more active pharmaceutical ingredients, wherein the compositions are in the form of high solids concentration pastes capable of being injected in relatively low volumes into an animal using standard commercially available syringes. The invention also provides methods of making such compositions, particularly those compositions comprising high molecular weight active ingredients (e.g., antibodies, enzymes and other proteins and peptides) at relatively high therapeutic concentrations in the high solids concentration pastes. The invention further provides methods of using such formulations in treating, preventing and/or ameliorating certain diseases and physical disorders in animals, including humans, in need thereof. The invention also provides kits comprising the formulations of the invention and a suitable syringe, which in some aspects may be pre-loaded or pre-filled with a composition of the invention.

A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells a thrombin inhibitor.

A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells a thrombin inhibitor.

Described herein is the design and construction of a class of lipoprotein targeting protease inhibitors. Small peptides with protease inhibitor activity are conjugated to hydrophobic, lipoprotein targeting molecules using, for instance, amine reactive chemistry. Methods of use of the resultant lipoprotein targeting protease inhibitor (antiprotease) molecules are also described. Also described is the production and use of protease inhibitor enriched HDL particles, as well as AlAT-peptide-enriched HDL particles, and their use in various therapeutic contexts.

Described herein is the design and construction of a class of lipoprotein targeting protease inhibitors. Small peptides with protease inhibitor activity are conjugated to hydrophobic, lipoprotein targeting molecules using, for instance, amine reactive chemistry. Methods of use of the resultant lipoprotein targeting protease inhibitor (antiprotease) molecules are also described. Also described is the production and use of protease inhibitor enriched HDL particles, as well as AlAT-peptide-enriched HDL particles, and their use in various therapeutic contexts.